Every person’s breast cancer experience is different, but there’s one thing that could help anyone facing a diagnosis: answers. Over the past 20 years, the Oncotype DX® test has empowered breast cancer patients to make more informed, personalized treatment decisions. #20YearsofOncotypeDX #BreastCancerAwarenessMonth | Exact Sciences

The Oncotype DX Breast Recurrence Score® test can help predict the chemotherapy benefit of a person with #BreastCancer.*​ Specifically, the test is for stage I-IIIA hormone receptor-positive, HER2-negative breast cancer. ​ Learn more about the Oncotype DX® test: https://bit.ly/41Js3Kr #CancerTreatment #CancerCare​ *Paik et al. J Clin Oncol. 2006;24(23):3726-3734; Albain et al. Lancet Oncol. 2010;11(1):55-65 | Until Everyone Knows

PUT CHEMO TO THE TEST. Oncotype DX® is the only test that knows if chemo is needed for early-stage breast cancer. | Until Everyone Knows

The Oncotype DX Breast Recurrence Score® test can provide personalized insights for certain people with breast cancer, whose cancer is:​ Stage I, II, or IIIa​ HR ​ HER2-​ Each patient receives an individualized score to help them make more informed treatment choices.​ Learn more about the Oncotype DX® test: bit.ly/3AXOiBE | Until Everyone Knows

The Oncotype DX Breast Recurrence Score® test is the only test that has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. And now, the National Comprehensive Cancer Network® (NCCN®) has updated its guidelines and recognized the Oncotype DX® test as the only assay that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes. Read more: https://exas.co/3dU3rEB | Exact

Every breast cancer is unique. Watch this video to learn how a genomic test, the Oncotype DX test, can help personalize treatment options or visit http://www.mybreastcancertreatment.org/ for more information. | Until Everyone Knows